Clal Bio Unit Plans $75m IPO in the U.S.

The shares represent 24.5% of the ownership in the company.

comments Print
MediWound, a Clal Biotechnology subsidiary that develops products for the treatment of severe burns and wound management, is in the process of trying to raise $75 million through an offering of 5 million...